#ESMO22: Amgen spotlights confirmatory win for KRAS G12C player Lumakras in lung cancer — but there's plenty more data to come
PARIS — Amgen came to Paris with a two-step plan to reveal confirmatory CodeBreak 200 trial data for its KRAS G12C drug Lumakras in non-small cell lung cancer. After tipping its cards ahead of the conference to stake a top-line claim — sans data — on hitting the primary endpoint for median progression-free survival over docetaxel at 12 months, we’re getting the initial snapshot that details just how the comparison stacks up.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.